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Antitumour activity of docetaxel (Taxotere
s) in hormone-dependent (HD) and hormone-independent (HID) prostate cancer
PAC120 xenograft model was previously reported, and its level was associated with HER2 protein expression. In the present study,
we evaluate the antitumour effects of docetaxel combined with trastuzumab (Herceptin
s), an anti-HER2 antibody. Although
trastuzumab alone had no effect on tumour growth, it potentiated the antitumour activity of docetaxel in HD tumours and more
strongly in HID variants. Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased
HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24h after docetaxel treatment, while HER2 protein and p-AKT
decreased. This was followed by an increase of HER2 protein 3 days (two-fold) after docetaxel treatment and by a strong HER2
release in the serum of treated mice; expression of phospho-ERK, p27, BCL2 and HSP70 concomitantly increased. Similar molecular
alterations were induced by docetaxel plus trastuzumab combination, except for that there was a transient and complete
disappearance of AR and HSP90 proteins 24h after treatment. We show that in addition to its known effects on tubulin and mitotic
spindles, docetaxel induces complex signalisation pathway mechanisms in surviving cells, including HER2, which can be
pharmacologically targeted. This study suggests that the docetaxel/trastuzumab combination may prove an effective therapeutic
approach for HER2-expressing hormone-refractory prostate cancer.
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Escape from androgen ablation therapy is a constant feature of
prostate cancer progression, leaving patients with few therapeutic
options. Hormone-refractory prostate cancer (HRPC) was re-
garded as chemoresistant, until the recent demonstration of taxane
activity (Petrylak et al, 1999). A preclinical in vivo study using our
PAC120 model of hormone-dependent (HD) human prostate
cancer xenograft confirmed these data (de Pinieux et al, 2001;
Oudard et al, 2003). A randomised phase II study demonstrated
the efficacy of docetaxel-based chemotherapy vs a mitoxantrone–
prednisone combination, significantly decrease PSA and prolongs
time to progression of metastatic HRPC patients (Oudard et al,
2005). Despite these encouraging preclinical and clinical data, the
therapeutic efficacy of taxane-based chemotherapy of HRPC
remains modest. A better knowledge of the mechanisms of tumour
hormonal escape and of key molecular targets is needed to design
more effective combination therapies for HRPC.
Several preclinical studies have implicated the ERBB family of
tyrosine kinase receptors, especially HER2, in the progression
of prostate cancer to a hormone-refractory state. The CWR22
hormone-independent prostate cancer xenograft expresses HER2
and its growth is inhibited in vivo by an anti-HER2 antibody (Agus
et al, 1999; Mendoza et al, 2002). Increased hormone independence
in prostate cancer cells was associated with androgen receptor
(AR) phosphorylation mediated by transfected HER2 (Craft et al,
1999; Yeh et al, 1999). A recent study in prostate cancer cell lines
showed that an HER2/ERBB3 signalling pathway protected the
AR from degradation by the ubiquitin–proteasome pathway and
enhanced AR transcriptional activity at low androgen concentra-
tions (Mellinghoff et al, 2004). Studies of clinical prostate cancer
samples, however, have produced mixed data, failing to firmly
establish a relationship between HER2 overexpression and
progression to hormone independence (Osman et al, 2001; Shi
et al, 2001; Savinainen et al, 2002; Calvo et al, 2003). HER2 gene is
overexpressed in 20–25% of invasive breast cancers and in 60%
of HRPC. Trastuzumab has antitumour activity in patients with
HER2-overexpressing breast cancer. A phase II clinical trial of
trastuzumab and docetaxel with HER2-overexpressing prostate
cancer has recently been conducted (Lara et al, 2002) and needs to
be completed.
In this study, we report the improvement of the docetaxel
response of prostate cancer xenografts PAC120 by combination
with trastuzumab (Herceptin
s, Roche, Neuilly sur Seine, France),
a humanised anti-HER2 antibody, and the idea is to understand
tumour biological mechanism after combination. We show
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sthat docetaxel induces an increase of tumour HER2 expression.
Trastuzumab, an anti-HER2 antibody which binds the ectodomain
of the HER2 receptor, markedly potentiates the antitumour activity
of docetaxel, an effect that is associated with early complete
degradation of AR and HSP90 proteins. This potentiation was
more pronounced in terms of survival delay and complete tumour
regression in hormone-independent (HID) tumour variants of
PAC120. The data suggest that docetaxel triggers an HER2-
mediated signalling pathway, which protects tumour cells from
taxane-induced alterations. The induction of HER2 opens a way
for the design of effective combination therapy in prostate cancer.
MATERIALS AND METHODS
In vivo studies
PAC120 was established as xenograft by serial subcutaneous
grafting of prostate cancer tissue into 8-10-week-old Swiss nu/nu
male mice (bred and maintained at the Institut Curie SPF animal
facility), as published (de Pinieux et al, 2001). The original tumour
xenotransplant was obtained by transurethral resection of a locally
recurrent primary prostate adenocarcinoma. PAC120 has a
Gleason grade 9 (5þ4) and is HD. Hormone-independent variants
were derived from PAC120-bearing mice after bilateral orchidec-
tomy. After tumour regression and regrowth, the tumours were
maintained under androgen deprivation by transplantation into
castrated males. Two HID variants, designated HID25 and HID28,
were selected and used after the fourth passage. Experiments were
performed under supervision of Ile de France-I ethical committee,
according to French regulations.
Tumour fragments (30mm
3) were grafted in the interscapular
subcutaneous tissue, one fragment per mouse, under anaesthesia
(Oudard et al, 2003). Tumour take was almost 100%. Tumour-
bearing mice were randomly distributed into groups of 7–12
assigned to control or treatment. Treatment was administered
when the tumours reached 60–200mm
3 in size. Docetaxel
(Taxotere
s, Aventis Laboratories, France) was extemporaneously
prepared according to the procedure used for the clinical
compound, and injected intraperitoneally (i.p.) at a dose of
20mgkg
 1 every 3 weeks, as already published (Oudard et al,
2003). Trastuzumab (Herceptin
s, Roche, France) was adminis-
tered weekly by the i.p. route at 10mgkg
 1. The combination
treatment was concurrently given on day 1 and every 3 weeks, with
weekly administration of trastuzumab. These experiments were
repeated twice for HID-25 and three times for PAC120 and HID28.
For histological and gene/protein expression analyses, mice
bearing PAC120 and HID tumours were killed at different times
after treatment, as indicated in the results section.
Tumour growth was assessed by measuring two perpendicular
diameters with calipers, twice weekly. Tumour volume (V) was
calculated by V¼a
2 b/2, where a is the width in mm and b is the
length in mm. Individual tumour volume relative to initial size
(RTV) and mean relative tumour volume SD per group were
calculated. Tumour growth inhibition (TGI) was calculated as the
ratio of RTV in the treated to control group at a given time  100.
Tumour growth delay (TGD) was the time in days required for
tumours to achieve a five-fold increase in initial volume. Median
survival was the time in days corresponding to the death of 50%
of mice per group, mice being ethically killed when their tumours
reached a volume of 2000mm
3. Statistical significance of the
differences was calculated using the two-sided Student’s t-test.
Histology and immunohistochemical studies
PAC120, HID25 and HID28 tumour samples were removed
from mice and immediately fixed in 10% formalin solution
and embedded in paraffin. The mitotic index was determined as
the average mitotic count in 10 high-power fields from analysis of
HES (haematoxylin and eosin safran)-stained 4-mm-thick sections.
The apoptotic index was determined as the percentage of apopto-
tic cells stained by asp175-cleaved anti-caspase 3 antibody
(Cell Signaling, Beverly, MA, USA), in 300 counted cells.
Immunostaining was performed on 4mm paraffin-embedded
sections. Endogenous peroxidase activity was blocked by incuba-
tion of samples in 0.3% hydrogen peroxide in methanol for 30min.
Tissue slides were microwaved in 0.01 M sodium citrate buffer (pH
6) near boiling for 20min. The sections were incubated with a
blocking solution (5% horse serum, 1% bovine serum albumin,
0.1% sodium azide, in PBS) for 30min. Primary antibodies for
HER2/neu/erbB2 (Zymed Laboratories, San Francisco, CA, USA)
and HSP90 (Calbiochem, Fontenay-sous-Bois, France) were
incubated at room temperature for 1h or at 41C overnight, at
1:50 dilution. After incubation with a biotinylated secondary
antibody (RTU Vectastain Elite kit, Vector Laboratories, Burlin-
game, CA, USA), the immunohistochemical reaction was visualised
using the avidin–biotin–peroxidase complex (ABC Vectastain
Elite kit, Vector Laboratories, Burlingame, CA, USA) with
diaminobenzidine tetrahydrochloride (DAB). Sections were
counterstained by Mayer’s haematein solution. For each anti-
body, appropriate positive and negative controls were tested
simultaneously.
Western blotting and ELISA protein analyses
Tumour samples (three tumours per treatment group) were
homogenised in NP40 lysis buffer (containing 0.5% Nonidet P40
in 50mM Tris–HCl, pH 8, 120mM NaCl, 1mM EDTA, 5mM NaF,
1m M Na3VO4 and protease inhibitor cocktail tablets (Roche
Applied Science, France)). Tumour lysates were incubated for 1h
at 41C with constant stirring. Protein samples (15–20mg protein)
were run on SDS polyacrylamide mini-gels and transferred to
PVDF membranes. Blots were incubated overnight at 41C with the
diluted primary antibody. After 1h of incubation at room
temperature with the appropriate peroxidase-linked secondary
antibody, immunoreactivity was detected by chemoluminescence
using an ECL kit (Amersham, Buckinghamshire, UK). Antibodies
were used at 1:50–1:2000 dilution. Total beta-tubulin (Sigma
Aldrich, Saint-Quentin, France); HER2/neu/erbB2 (Zymed
Laboratories); phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204),
phospho-AKT (Ser 473) (Cell Signaling Technologies, Beverly, MA,
USA); p27/KIP1 (Oncogene Research Products, Fontenay-sous-
Bois, France); BCL-2 (DAKO, Danemark) Androgen receptor
(Upstate Biotechnology, Euromedex, Souffelweyersheim, France);
HSP90, (Calbiochem, Fontenay-sous-Bois, France), HSP70 (Inter-
chim, Montluc¸on, France); Actin (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Relevant HPR-conjugated goat or rabbit
antibodies (Santa Cruz Biotechnology) were used for detection of
primary antibody. For quantitative analysis, the intensity of the
signals was determined using ImageJ software then normalised
relative to actin and control group.
For the measurement of serum HER2 levels, mice (three per
group) were treated and bled 3 days after docetaxel treatment and
the serum harvested and frozen at  201C until use. Three mice
were used as controls. The seric HER2 levels were measured by an
ELISA kit at a densitometry of 492nm (HER-2/neu Microtiter
ELISA, Dako Cytomation, Carpinteria, CA, USA) according to the
manufacturer’s protocol.
Real-time reverse transcription (RT)–polymerase chain
reaction (PCR) analysis of gene expression
Tumour samples (five tumours from each treatment group) were
harvested and snap frozen in liquid nitrogen. Total RNA was
prepared with Trizol as described by the manufacturer (Invitrogen,
Gercy Pontoise, France). RNA quality was confirmed by the
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sRNA 6000 assay (Agilent Technologies 2100 Bioanalyser,
Massy, France). Reverse transcription of RNA was performed
by random priming (cDNA cycle Kit, Invitrogen) using 2mg
of total RNA. Real-time RT–PCR and the design of primers were
as described (Legrier et al, 2004). Primers designed with
the Primer Express software (ABI, Les Ulis, France) were
the following: AR: S: CTTGTGTCAAAAGCGAAATGGGC, AS: CA
AAACATGGTCCCTGGCAGTC; HER2: S: TGGAGACCCGCTGAA
CAATAC, AS: CCTTTCAAGATCTCTGTGAGGCTT; HPRT:S :
GCTTTCCTTGGTCAGGCAGTATAA, AS: AAGGGCATATCCTA
CAACAAACTT. For normalisation, transcripts of the HPRT gene
encoding human hypoxanthine phosphoribosyltransferase, pre-
viously identified as the most stable reference gene for this
experimental sample set using the geNorm software (Vandesompele
et al, 2002), was used as endogenous RNA controls. Data
represented median of five tumours for each treatment group
and were expressed relatively to control group. Each PCR reaction
was performed in triplicate.
RESULTS
Response of PAC120 and HID variants xenografts to
docetaxel alone or combined with trastuzumab
Following transplantation, PAC120 xenografts required 40 days
on average to reach a volume of 100mm
3, with a tumour take of
almost 100%. Docetaxel treatment was well tolerated, without
significant loss of weight. Docetaxel inhibited tumour growth
by 63% at day 33 (P¼0.13) and prolonged the TGD 1.8-fold
(Figure 1A; Table 1). One complete tumour regression was
registered. Trastuzumab alone had no effect on the tumour, and
was perfectly tolerated. When given with docetaxel, trastuzumab
potentiated its antitumour effect, leading to a tumour growth
inhibition of 85% at day 33 (Po0.03). Transient tumour
regressions were observed in seven out of eight, one leading to a
complete regression. The difference in TGI between the docetaxel
plus trastuzumab combined treatment and the treatment by
docetaxel alone was statistically significant (P¼0.05 at day 51).
When docetaxel was split into two doses of 10mgkg
 1, given at
days 1 and 8 every 3 weeks, no reduction of tumour growth was
obtained and the combination with trastuzumab did not induce
any response (data not shown).
The HID28 and HID25 xenografts growing in castrated males
reached a 100mm
3 volume after 55 and 60 days, respectively, with
a tumour take of almost 100%. Docetaxel inhibited the growth of
HID25 by 64% at day 45 (P¼0.02) and prolonged the TGD 2.3-fold
(Figure 1B, Table 1). The treatment was maintained for 120 days
(six cycles of treatment) without any tumour growth (data not
shown) and was well tolerated (no loss of weight). The
trastuzumab plus docetaxel combination treatment reduced
tumour size by 87% at day 45 (Po0.001), leading to complete
Table 1 Effects of docetaxel alone or with trastuzumab on growth
parameters of PAC120 and HID25 and HID28 variants
Tumour Treatment
Tumour
GD in
days
a
Survival
delay in
days
b
Tumour
regression
c Cures
d
PAC120 None 20 33 0/9 0
Docetaxel 36 64 1/9 (11%) 0
Trastuzumab 20 33 0/8 0
Docetaxel/
trastuzumab
64 464 7/8 (88%) 1
HID25 None 29 47 0/10 0
Docetaxel 67 492 0/11 (0%) 0
Docetaxel/
trastuzumab
492 492 11/13 (85%) 6 (46%)
HID28 None 15 35 0/10 0
Docetaxel 82 100 4/10 (40%) 0
Trastuzumab 14 32 0/8 0
Docetaxel/
trastuzumab
4132 4132 7/8 (88%) 5 (71%)
aTumour growth delay (GD) was calculated as the median number of days required
to observe a five times increase in initial tumour volume.
bSurvival median delay in
days after start of treatment.
cNumber of mice with a reduction of tumour size after
start of treatment to the total number of mice.
dNumber of mice without tumour (no
regrowth) at the end of experiment (killing of mice) out of the total number of mice.
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Figure 1 Effect of docetaxel and trastuzumab, alone or combined, on
the growth of PAC120, HID25 and HID28 prostate cancer xenografts.
Tumour growth curves in mice that were untreated (empty circles), treated
with docetaxel, 20mgkg
 1 every 3 weeks (empty triangles), trastuzumab,
10mgkg
 1 weekly (filled squares) and docetaxel plus trastuzumab (filled
lozenges). (A) Growth curves of the PAC120 HID prostate cancer
xenograft. (B) Growth curves of the HID25 HID prostate cancer xenograft
grown in castrated mice. (C) Growth curves of the HID28 HID prostate
cancer xenograft grown in castrated mice. Bars represent s. d.
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stumour regressions in six out of mice at day 180. Docetaxel
inhibited the growth of HID28 by 77% at day 38 (Po0.01),
prolonged the TGD by 5.4 times (Figure 1C, Table 1) and induced
complete tumour regressions in five out of eight mice. Combina-
tion of trastuzumab with docetaxel potentiated tumour growth
inhibition (98% at day 38) and prolonged the survival up to 132
days, TGD being not reached. Trastuzumab alone had no effect on
tumour growth (as shown in HID28, Figure 1C).
Alteration of tumour histology after docetaxel or
docetaxel/trastuzumab combination treatment
PAC120 and HID28 are high-grade adenocarcinomas that display
similar differentiation with rare glandular structures, whereas
HID25 is mucinous as previously described (Legrier et al, 2004)
(Figure 2A, D and G). Mitoses were numerous in all tumours
(mitotic index was 21, 8 and 11% in PAC120, HID25 and HID28,
respectively). At 3 days after docetaxel treatment, many cells were
blocked in mitosis, increasing the mitotic index to 40, 29 and 56%
in PAC120, HID25 and HID28, respectively. Nuclear abnormalities,
such as multinucleation and multipolar division, were numerous
(Figure 2B, E and H). At 3 days after the docetaxel plus
trastuzumab combination treatment, the mitotic index was of 13,
5 and 20% in PAC120, HID25 and HID28, respectively (Figure 2C,
F and I). Apoptosis indexes, evaluated by anti-caspase 3 anti-
body immunostaining, remained low in all xenografts, whether
treated or not. In all tumours treated with the docetaxel plus
trastuzumab combination, tumour cells appeared elongated with
ABC
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Figure 2 Histological features of PAC120, HID25 and HID28 xenografts (HES staining,  200 magnification). Left panels, untreated tumours; middle
panels, docetaxel-treated tumours; right panels, docetaxel plus trastuzumab-treated tumours. (A) PAC120 tumours were characterised by a Gleason score
of 9 (5þ4) with compact sheets of tumour cells surrounded by a fine murine stroma. (B) At 3 days after docetaxel treatment, accumulation of mitotic cells
is visible (arrows). (C) At 47 days after treatment with docetaxel plus trastuzumab, the tumour has markedly regressed, leaving large areas of empty fibro-
adenomatous tumour stroma (arrow), invaded by murine cells. (D) HID25 tumours display mucinous differentiation with principally signet-ring cells. (E)A t3
days after docetaxel treatment, accumulation of numerous and abnormal mitotic cells (arrows) (HES 400). (F) At 3 days after treatment with the
docetaxel plus trastuzumab combination, presence of elongated tumour cells with hyperchromatic nuclei (arrows). (G) HID28 shows histologic features
similar to that of PAC120. (H) At 3 days after docetaxel treatment, there is accumulation of mitotic cells, multipolar divisions and few apoptotic bodies
(arrows). (I) At 3 days after treatment with the docetaxel plus trastuzumab combination, note the presence of enlarged and mitotic tumour cells in the
middle of compact cellular masses, surrounded by elongated cells (arrows). Percent indicates the mitotic index.
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shyperchromatic nuclei appeared 3 days after treatment. This
morphological alteration was not apparent after single-agent
treatment (Figure 2I). After 47 days (three cycles of treatment),
residual tumours were composed of small foci of cells within a
stromal matrix (Figure 2C). Treatment with trastuzumab alone did
not affect any histological parameter (data not shown).
Treatment-induced molecular alterations in HID28
prostate cancer xenografts
Western blotting (Figure 4) was used to evaluate changes in
expression of b-tubulin, HER2, p-ERK, p-AKT, p27, BCL2, AR,
HSP90 and HSP70 induced by treatment with docetaxel alone or
the trastuzumab plus docetaxel combination in HID28 tumours, a
very high responder. Tumour samples were harvested from groups
of three mice and analysed 1, 3 and 15 days after one cycle of
treatment. There were few variations between triplicate data
corresponding to the three mice per group; consequently, the
results shown corresponded to one representative mouse. The
chosen kinetics allowed to evaluate optimal expression of different
proteins of interest. Total b-tubulin increased after both treatment,
except at day 3 after combination. HER2 protein levels (basal level
at 0.47 in arbitrary units (a.u.) in controls, decreasing after 24h)
increased (two-fold) at day 3 after docetaxel treatment and at 24h
after the docetaxel plus trastuzumab combination then decreased
at 3 and 15 days after combination treatment. At 3 days after
docetaxel treatment, anti-HER2 antibody stained the membrane of
tumour cells, more intensively than in the control group (Figure
3A and B). At day 15, in the group treated with the combination,
HER2 expression was lower, restricted to the membrane of mitotic
cells (Figure 3C). In the serum of control mice bearing HID28
xenografts, the median level of soluble HER2 was 1.1ngml
 1. At
3 days after docetaxel treatment, it increased to more than
18ngml
 1 (saturation of the kit) showing a release of free HER2 in
the serum of three treated mice. Trastuzumab treatment alone did
not induce at any time any change in the protein expression profile
of HID28.
Phospho-ERK was strongly increased 3 days after docetaxel and
1, 3 and 15 days after the docetaxel/trastuzumab combination.
Phospho-AKT (Ser473) decreased transiently 24h after docetaxel
treatment and returned to its initial level 3 days after treatment.
Globally, no alteration of p-AKT level was observed except a
decrease 24h after the docetaxel/trastuzumab combination treat-
ment. The amount of p27 CDK inhibitor protein was increased 1
and 3 days after both treatments and returned to control levels
after 15 days. Elevation of BCL2 was immediate after both
treatments and decreased 15 days after combination.
The androgen receptor was expressed at constant levels in
tumours from untreated mice (basal level at 0.32 a.u.) or from mice
treated with docetaxel alone. Androgen receptor (AR) expression
was undetectable 24h after the docetaxel plus trastuzumab
treatment, coming back to low levels at day 3 with a complete
restoration by day 15. HSP90 expression followed a similar pattern.
After docetaxel treatment, anti-HSP90 antibody homogeneously
stained the cytoplasm of tumour cells, except in mitotic cells
(Figure 3D and E). After 24h of combination treatment, the anti-
HSP90 staining disappeared, consistent with Western blotting data
(Figure 3F). HSP70 protein levels in Western blotting increased
after docetaxel alone or combined, then progressively decreased.
The levels at HER2 and AR mRNA were analysed by real-time
RT–PCR (Figure 5). Compared with control group (basal level 0.13
a.u), AR mRNA increased two-fold 24h after docetaxel treatment
and remained at this level after 3 and 15 days. After treatment
with trastuzumab alone, AR mRNA levels were unchanged.
The docetaxel plus trastuzumab combination induced a four-,
13- and five-fold increase in AR mRNA 1, 3 and 15 days after
treatment, respectively. This contrasts with the total disappearance
of AR protein day after the combination treatment and with AR
protein levels still below baseline at day 3. The expression of HER2
mRNA was detected in control HID28 tumours (basal level at 0.01).
Reverse transcriptase–polymerase chain reaction data showed an
ABC
DEF
Figure 3 Expression pattern of HER2 and HSP90 in HID28 xenografts by immunohistochemistry. Left two panels, untreated tumours; middle two panels,
docetaxel-treated tumours at day 3; right two panels, docetaxel/trastuzumab treatment ( 200 magnification). HER2 immunodetection. (A) The anti-HER2
antibody staining is weak, diffuse and focal, stronger in mitotic cells (arrows). (B) HER2 staining is increased in all the tumour cells with preferential
membrane staining. (C) Immunostaining was restricted to the membrane of mitotic cells at day 15. HSP90 immunodetection. (D) Anti-HSP90 antibody
stained the cytoplasm of HID28 tumour cells. (E) All tumour cells are stained except mitotic cells (arrow). (F) The anti-HSP90 staining disappeared from all
tumour cells, apart from rare cells at day 1.
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sincreased expression of HER2 mRNA after trastuzumab treatment
less than after docetaxel alone or combination. HER2 mRNA levels
were increased at all time points by all treatments, between 4–25-fold.
DISCUSSION
The use of taxanes for treating hormone refractory prostate
cancers has started to change the outcome of these patients;
but, although encouraging, the therapeutic benefits need to be
improved. To reach this goal, a better understanding of the
biological processes initiated in taxane-treated tumours might lead
to a design of more effective combination therapies. In a previous
publication, we showed that the sensitivity of PAC120 prostate
tumour and its HID variants xenografts to docetaxel (Oudard et al,
2003) was related with the constitutive level of HER2 mRNA
expression. Here, we reported the potentiating effects of combi-
ning the docetaxel with trastuzumab, a humanised HER2 anta-
gonistic antibody. Trastuzumab treatment alone was inactive in
PAC120 xenografts and in HID28 variant, distinguishing our
model from the CWR22 prostate cancer xenograft model, which
overexpresses HER2 and is sensitive to Trastuzumab (Agus et al,
1999). This absence of response to trastuzumab alone has recently
been reported in clinical trial in prostate cancer (Lara et al, 2004).
Trastuzumab response in tumour types other than breast
carcinoma remains to be determined. Docetaxel treament reduced
tumour growth of the three tumour variants. Antitumoural effects
induced by the docetaxel/trastuzumab combination were superior
to that induced by docetaxel alone, in all growth parameters,
percent of inhibition, survival prolongation and complete regres-
sions. The effects of the combination docetaxel/trastuzumab have
already been reported in breast cancer, but are not so clear. Few
clinical trials have been conducted in prostate cancer (Small et al,
2001; Lara et al, 2004) with some encouraging data in the treatment
of advanced prostate cancer.
Histology of docetaxel-treated tumours showed alterations
typical of taxanes, such as cell cycle arrest and abnormal mitoses.
Additionally, after docetaxel/trastuzumab combination treatment,
numerous tumour cells appeared elongated, like ‘flattened
balloons’ at the interface between tumour cords and murine
stroma, whereas tumour cells are typically round in the not-treated
tumours. This observation suggested a reduction of tumour cell
tonicity, due to alterations of cytoplasmic, microtubules, induced
by docetaxel treatment and potentiated by trastuzumab. We
concluded that docetaxel had the expected effects on the mitotic
spindle and the cytoskeleton and we postulated that trastuzumab
enhanced the alterations of microtubules by inhibiting an HER2-
dependent repair through a reduced phosphorylation. Our data
pointed to a causal relationship between HER2 signalling,
docetaxel-induced alterations of microtubules and potentiated
tumour cell death by trastuzumab.
The primary target of taxanes is b-tubulin, which is part of the
mitotic spindle and of cytoplasmic microtubules. Taxanes block
tubulin depolymerisation, resulting in impairment of cellular
mitosis (Horwitz, 1994), generating nuclear abnormalities
and multipolar divisions, ultimately leading to cell death (Abal
et al, 2003). Taxane-induced tubulin alterations may also affect
microtubule-associated proteins (MAPS) (Burns et al, 1984,
Haycock et al, 1992), potentially leading to multiple cellular
dysfunctions. Microtubule-associated proteins are among the
protein clients of heat-shock proteins (HSP70 and HSP90),
themselves associated with and stabilising numerous proteins
such as HER2, AKT and the AR (Georget et al, 2002). Numerous
studies indicate that the function of MAPs in microtubule integrity
is regulated by phosphorylation reactions via kinases (Horne and
Guadagno, 2003).
Docetaxel alone or combined to trastuzumab affected the
expression of several proteins involved in HER2 signalling in our
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Figure 5 Real-time RT–PCR quantitation of AR and HER2 mRNA
transcripts in HID28 xenograft, after one cycle of treatment. Median levels
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Figure 4 Western blotting analysis of protein expression in a
representative HID28 xenograft, after one cycle of treatment. Untreated
tumours (lane 1), 1 or 3 days after docetaxel treatment (lanes 2 and 3,
respectively); 1, 3 or 15 days after docetaxel plus trastuzumab treatment
(lanes 4, 5 and 6, respectively). Actin (45kDa) was used as a control. Signals
correspond to b-tubulin (110kDa), HER2 (185kDa), phospho-ERK (42–
44kDa), phospho-AKT (60kDa), p27 (27kDa), BCL2 (26kDa) AR
(110kDa), HSP90 (90kDa) and HSP70 (70kDa). Histograms of proteic
expression of HER2, AR and HSP90 in treated tumours reported to that of
controls, day 1, 3 or 15 after docetaxel treatment alone or combined with
trastuzumab.
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sxenograft model. Elucidation of differences of protein expression
and interaction between different pathways will be important in
the design of targeted treatment of advanced prostate cancer. We
found that tumour HER2 mRNA increased 24h after docetaxel
treatment, followed at 72h by an increase in HER2 protein and
release of free HER2 in the serum of treated mice. Detection of
HER2 at different times might correspond to restart in the cycle of
survival cells. The role of HER2 in prostate cancer progression is
still debated, with divergent reports about the level of HER2
expression in HRPC (Reese et al, 2001; Shi et al, 2001; Di Lorenzo
et al, 2002; Fossa et al, 2002; Mendoza et al, 2002; Savinainen et al,
2002; Calvo et al, 2003; Hernes et al, 2004). These discrepancies
could be due to the methodology used for detecting HER2,
designed for detection in breast cancers, and it might be
inadequate for prostate cancer tissue (Simon et al, 2001). In the
present study, an overnight incubation with the antibody was
performed. Alternatively, HER2 overexpression may play a role in
hormonal escape in only a subset of tumours, since other potential
mechanisms, such as increased AR expression or mutations in the
AR, have also been described (Edwards et al, 2003). The increase in
HER2 and phospho-ERK levels following docetaxel treatment is
consistent with the notion that MAPKinase activation constitutes
a cell survival/repair response to docetaxel. Similar conclusions were
drawn from studies in which combinations of taxanes and
pharmacological MAPK inhibitors were additive and correlated with
MAPK activation following taxane treatment in various tumour cell
lines (McDaid and Horwitz, 2001; Zelivianski et al, 2003).
Docetaxel alone reduced HSP90 protein level 24h after
treatment, but did not affect that of AR. Combined treatment
induced a simultaneous disappearance of both AR and HSP90,
indicating their close relationship. The loss of the AR protein
occurred in spite of an increase in AR transcription, suggesting
post-translational degradation. It is known that cytoplasmic AR
degradation is prevented by its binding to heat-shock protein
HSP90 (Georget et al, 2002). This could account for the
potentiating effect of trastuzumab on docetaxel in the specific
context of prostate cancer cells. Indeed, several recent studies
suggest that AR continues to play a key role in the survival and
proliferation of HID prostate cancers via HER2 signalisation (Craft
et al, 1999; Yeh et al, 1999), explaining the role of trastuzumab in
the combination with docetaxel.
However, in the present study, the potentiation of docetaxel by
trastuzumab was not paralleled by a decrease in either phospho-
ERK or phospho-AKT levels, suggesting that inhibition of another
signalling pathway was involved in the degradation of AR/HSP90.
In support of this possibility, a recent study using a dual EGFR/
HER2 kinase inhibitor in prostate cancer cell lines showed that an
HER2/ERBB3 signalling pathway protected the AR from degrada-
tion at low androgen concentrations through an AKT-independent
pathway (Mellinghoff et al, 2004).
Our finding that docetaxel can induce an increase of HER2
transcription and expression in a human prostate cancer model is
paralleled by a release of HER2; detection of seric HER2 could
be searched for in patients after docetaxel treatment. Our data
show that docetaxel/trastuzumab combination caused a simulta-
neous hormone-receptor and HSP90 degradation and enhances the
antitumour efficacy of docetaxel, suggesting that complete
inactivation of AR could affect HID prostate cancers. This
provides preclinical support for exploring this therapeutic strategy
in HRPC patients.
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